Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2026 · third_quarter · Q3
340B Reform Patient Access to Healthcare
Research funding
Intellectual Property
Source: Senate LDA
PBM Reform Most Favored Nation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2026 · second_quarter · 2T
Financial regulations
Filing targets: SENATE
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2026 · second_quarter · Q2
Intellectual Property
Research funding
PBM Reform Most Favored Nation
340B Reform Patient Access to Healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2026 · first_quarter · Q1
Financial regulations
Tax credits
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2026 · first_quarter · Q1
Research funding
PBM Reform Most Favored Nation
Intellectual Property
340B Reform Patient Access to Healthcare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · fourth_quarter · Q4
Tax credits
Financial regulations
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · fourth_quarter · Q4
340B Reform Patient Access to Healthcare
PBM Reform
Research funding
Bioscience Intellectual Property
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · third_quarter · Q3
Tax credits
Financial regulations
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · third_quarter · Q3
340B Reform Patient Access to Healthcare
PBM Reform
Research funding
Bioscience Intellectual Property
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · second_quarter · Q2
Tax credits
Financial regulations
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · second_quarter · Q2
340B Reform Patient Access to Healthcare
PBM Reform
Research funding
Bioscience Intellectual Property - state rankings
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · first_quarter · Q1
Tax credits
Financial regulations
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2025 · first_quarter · Q1
340B Reform Patient Access to Healthcare
PBM Reform
Research funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · fourth_quarter · Q4
Tax credits
Research on Tax Credit(s) issues by Native American Nations on projects, or under programs, for the economic benefit of Tribal Nations or its members.
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · fourth_quarter · Q4
Rebate reforms
PBM Reform IRA implementation
Innovation economy Research & Development funding Patents
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · third_quarter · Q3
Research on Tax Credit(s) issues by Native American Nations on projects, or under programs, for the economic benefit of Tribal Nations or its members.
Tax credits
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · third_quarter · Q3
Innovation economy Research & Development funding Patents
Non-interference Rebate reforms
PBM Reform IRA implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · second_quarter · Q2
Research on Tax Credit(s) issues by Native American Nations on projects, or under programs, for the economic benefit of Tribal Nations or its members.
Tax credits
Filing targets: Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · second_quarter · Q2
Non-interference Rebate reforms
Innovation economy Research & Development funding Patents
PBM Reform IRA implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHITE RIVER ENERGY CORP. via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · second_quarter · RR
Providing public affairs & government relations services on tax credits and Native American Nations
Providing public affairs & government relations services on tax credits and Native American Nations
Providing public affairs & government relations services on tax credits and Native American Nations
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2024 · first_quarter · Q1
PBM Reform IRA implementation
Non-interference Rebate reforms
Innovation economy Research & Development funding Patents
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2023 · fourth_quarter · Q4
Non-interference Rebate reforms
Innovation economy Research & Development funding
PBM Reform IRA implementation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2023 · third_quarter · Q3
PBM Reform IRA implementation
Innovation economy Research & Development funding
Non-interference Rebate reforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2023 · second_quarter · Q2
PBM Reform IRA implementation 340B Reform
Non-interference Rebate reforms
Innovation economy Research & Development funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2023 · first_quarter · Q1
Innovation economy Research & Development funding
PBM Reform IRA implementation 340B Reform
Non-interference Rebate reforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via CONVERGENCE PUBLIC AFFAIRS LLC
2023 · first_quarter · RR
IRA PBM Reform Cost of prescription medications Economic impact of the biopharmaceutical industry Access to medicines Chronic diseases research and management Drug importation Value of medicine
IRA PBM Reform Cost of prescription medications Economic impact of the biopharmaceutical industry Access to medicines Chronic diseases research and management Drug importation Value of medicine
IRA PBM Reform Cost of prescription medications Economic impact of the biopharmaceutical industry Access to medicines Chronic diseases research and management Drug importation Value of medicine
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Providing public affairs & government relations services on tax credits and Native American Nations
Providing public affairs & government relations services on tax credits and Native American Nations
IRA PBM Reform Cost of prescription medications Economic impact of the biopharmaceutical industry Access to medicines Chronic diseases research and management Drug importation Value of medicine
IRA PBM Reform Cost of prescription medications Economic impact of the biopharmaceutical industry Access to medicines Chronic diseases research and management Drug importation Value of medicine